J&J Expands Ketamine Case With Spravato Monotherapy Indication
On the US market since 2019 for treatment-resistant depression in tandem with oral antidepressants, J&J’s new indication allows for more flexibility.

On the US market since 2019 for treatment-resistant depression in tandem with oral antidepressants, J&J’s new indication allows for more flexibility.